Zynerba Pharmaceuticals (ZYNE) PT Lowered to $8.50 at Roth Capital, After Study Misses Endpoints Jun 30, 2020 02:15PM
Zynerba Pharmaceuticals (ZYNE) PT Raised to $11 at Roth Capital, Following Drug Trial Results May 27, 2020 02:25PM
Companies with NDRs 5/19 May 19, 2020 06:48AM
UPDATE: Roth Capital Transfers Coverage on Zynerba Pharmaceuticals (ZYNE) at Buy Dec 31, 2019 09:40AM
Roth Capital Starts Zynerba Pharmaceuticals (ZYNE) at Buy Apr 30, 2019 08:21AM


Aug 15, 2017 08:31AM Roth Capital Upgrades Zynerba Pharmaceuticals (ZYNE) to Buy
Aug 8, 2017 11:25AM Roth Capital Downgrades Zynerba Pharmaceuticals (ZYNE) to Neutral
Feb 9, 2017 07:35AM Zynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Jan 19, 2017 09:17AM Zynerba Pharma (ZYNE) Prices 2.8M Shares at $18 Per Share
Jan 19, 2017 09:16AM Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Mar 17, 2016 08:34AM Roth Capital Starts Zynerba Pharmaceuticals (ZYNE) at Buy